BD, a global leader in medical technology, has announced the successful completion of its acquisition of Edwards Lifesciences Critical Care product Group. BD sophisticated Patient Monitoring, a global leader in sophisticated monitoring solutions, will now operate as the acquired business unit. The integration of monitoring technologies and AI-enabled clinical decision tools in this acquisition fortifies BD's portfolio of smart connected care solutions. Minimally invasive sensors, tissue oximetry sensors, noninvasive cuffs and monitors, and the renowned Swan Ganz pulmonary artery catheter comprise the product line of BD Advanced Patient Monitoring. BD's monitoring and infusion platforms are integrated to facilitate advancements in closed-loop hemodynamic monitoring and IV fluid administration.
Kate Szyman, who was previously the corporate Vice President of Edwards, now assumes the role of Global President for BD Advanced Patient Monitoring. The Executive Vice President and President of BD's Medical segment, Mike Garrison, is her supervisor. The business will continue to operate in Irvine, California, in accordance with BD's connected care strategy. The August 2024 earnings report from BD disclosed that the acquisition will have an immaterial impact on its fiscal year 2024 guidance. The Transaction Announcement Press Release and Investor Presentation are accessible on BD's investor page for additional information.
